Could the Ebola virus matrix protein VP40 be a drug target?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 2, 2014, Pages 115-120

  Stahelin, Robert V ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Ebola; Filamentous virus; Lipid protein interaction; Oligomerization; Plasma membrane; Viral assembly; Viral budding; Virus; VP40

Indexed keywords

PROTEIN INHIBITOR; PROTEIN VP40; PROTEIN VP40 INHIBITOR; UNCLASSIFIED DRUG;

DEMOCRATIC REPUBLIC CONGO; DRUG TARGETING; EBOLA VIRUS; EPIDEMIC; FILOVIRUS; HUMAN; MARBURG VIRUS; NONHUMAN; PANDEMIC; PROTEIN EXPRESSION; REVIEW; UGANDA; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENE; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

ANIMALS; HEMORRHAGIC FEVER, EBOLA; HUMANS; NUCLEOPROTEINS; VIRAL CORE PROTEINS;

EID: 84892619367     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.863877     Document Type: Review

References (30)

1. Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013;9:e1003389
2. Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5:190ra79
3. Zhang AP, Bornholdt ZA, Liu T, et al. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog 2012;8:e1002550
4. Cote M, Misasi J, Ren T, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011;477:344-8
5. Chang J, Warren TK, Zhao K, et al. Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res 2013;98:432-40
6. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16:991-4
7. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375:1896-905
8. Fabozzi G, Nabel CS, Dolan MA, et al. Ebola proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol 2011;85:2512-23
9. Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013;5:199ra113
10. Qiu X, Alimonti JB, Melito PL, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011;141:218-27
11. Garcia M, Cooper A, Shi W, et al. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med 2012;4:123ra24
12. Kolokolstov AA, Adhikary S, Garver J, et al. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrophostin. Arch Virol 2012;157:121-7
13. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res 1995;39:129-50
14. Noda T, Sagara H, Suzuki E, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002;76:4855-65
15. Yadav SS, Wilson SJ, Bieniasz PD. A facile quantitative assay for viral particle genesis reveals cooperativity in virion assembly and saturation of an antiviral protein. Virology 2012;429:155-62
16. Liu Y, Lee MS, Olson MA, et al. Bimolecular complementation to visualize filovirus VP40-host complexes in live mammalian cells: toward the identification of budding inhibitors. Adv Virol 2011;2011:341816
17. Bornholdt ZA, Noda T, Abelson DM, et al. Structural rearrangement of Ebola virus VP40 begets multiple functions in the viral life cycle. Cell 2013;154:763-74
18. Dessen A, Volchkov V, Dolnik O, et al. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J 2000;19:4228-36
19. Hoenen T, Biedenkopf N, Zielecki F, et al. Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J Virol 2010;84:7053-63
20. Scianimanico S, Schoehn G, Timmins J, et al. Membrane association induces a conformational change in the Ebola virus matrix protein. EMBO J 2000;19:6732-41
21. Soni SP, Adu-Gyamfi E, Yong SS, et al. The Ebola virus matrix protein deeply penetrates the plasma membrane: an important step in viral egress. Biophys J 2013;104:1940-9
22. Gomis-Ruth FX, Dessen A, Timmins J, et al. The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure 2003;11:423-33
23. Adu-Gyamfi E, Soni SP, Xue Y, et al. The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J Biol Chem 2013;288:5779-89
24. Mim C, Unger VM. Membrane curvature and its generation by BAR proteins. Trends Biochem Sci 2012;37:526-33
25. Miao B, Skidan I, Yang J, et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci USA 2010;107:20126-31
26. Tamilvanan T, Hopper W. High-throughput virtual screening and docking studies of matrix protein VP40 of ebola virus. Bioinformation 2013;9:286-92
27. Hogue IB, Llewellyn GN, Ono A. Dynamic association between HIV-1 Gag and membrane domains. Mol Biol Int 2012;2012:979765
28. Ternois F, Sticht J, Duquerroy S, et al. The HIV-1 capsid protein C-terminal domain in complex with a viral assembly inhibitor. Nat Struct Mol Biol 2005;12:678-82
29. Matyas GR, Wieczorek L, Bansal D, et al. Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of b-chemokines. Biochem Biophys Res Commun 2010;402:808-12
30. Vieria CR, Munoz-Olaya JM, Sot J, et al. Dihydrosphingomyelin impairs HIV-1 infection by rigidifying liquidordered membrane domains. Chem Biol 2010;17:766-75